Australia-based Mayne Pharma announced on 15 March 2018 that it had launched a generic version of doxycycline monohydrate immediate release (IR) capsules (50, 75 and 100 mg) in the US.
Australia’s Mayne Pharma launches generic antibiotic in US
Generics/News
|
Posted 13/04/2018
0
Post your comment
Doxycycline IR capsules are a generic alternative to Aqua Pharmaceutical’s Monodox, which is a tetracycline-class antibacterial indicated for the treatment of a number of infections, including adjunctive therapy in severe acne.
Mayne Pharma makes both brand-name and generic drugs. ‘This launch will further broaden Mayne Pharma’s dermatology portfolio’, according to Mayne Pharma’s CEO Scott Richards.
The company markets more than 55 products and has a growing pipeline of around 30 drugs targeting the US market with sales of more than US$5 billion. According to IQVIA, doxycycline IR capsules had annual US sales of approximately US$30 million for the 12 month period ending 31 January 2018.
Related articles
Generic antibiotics could be contributing to bacterial resistance
FDA approval for generic antibiotic and arrhythmia drugs
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2018 Pro Pharma Communications International. All Rights Reserved.
Source: Mayne Pharma
Research
Japan’s drug shortage crisis: challenges and policy solutions
Saudi FDA drug approvals and GMP inspections: trend analysis
Related content
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Post your comment